News
Wed, 07 Aug 2024 06:00:00 -0400
Wed, 07 Aug 2024 06:00:00 -0400
Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to USD 19.3 billion in the first six months of 2024
|
PROFIT AND LOSS |
H1 2024 |
H1 2023 |
Growth as reported |
Growth at CER* |
|
USD million |
|
|
|
|
|
Net sales |
19,339 |
15,633 |
24% |
25% |
|
Operating profit |
8,376 |
7,099 |
18% |
19% |
|
|
|
|
|
|
|
Net profit |
6,590 |
5,698 |
16% |
N/A |
|
Diluted earnings per share (in USD) |
1.47 |
1.26 |
17% |
N/A |
|
* CER: Constant exchange rates (average 2023). ** For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.0 = DKK 6.89834 and the period-end exchange rate of USD 1.0 = DKK 6.96637 |
||||
Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the sales growth in the first half of 2024, which has enabled us to raise the outlook for the full year. The growth is driven by the increased demand for our GLP-1-based diabetes and obesity treatments, and we continue to reach more patients with our innovative treatments. Within R&D, we are very pleased with the first phase 3 trial results with Mim8 and its potential for people living with haemophilia A, and with the recent recommendation for a label extension for cardiovascular risk reduction for Wegovy® in the EU."
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.
Contacts for further information
Media:
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
Investors:
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
Sina Meyer
+45 3075 6656
azey@novonordisk.com
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com